This Career Development Program (CDP) will be used to prepare new Moffitt investigators at the rank of Assistant Member (Assistant Professor) or equivalent, particularly those already in the field of cutaneous malignancy research, or established Moffitt investigators at the rank of Associate Member (Associate Professor) or higher who are new to the field for careers in translational research of cutaneous malignancies. It will also ease their transition to independence as investigators either in the laboratory or as clinical trialists. The Moffitt Skin SPORE career development program will provide guidance, advice, mentoring, evaluation, and financial resources for continuing support for up to two faculty-level persons per year for 2-3 years each. All prospective projects have a mentor listed that is affiliated with the Skin SPORE or the Comprehensive Melanoma Research Center (CMRC) at Moffitt. The goal is to allow appropriate and motivated individuals to develop an independent research career in translational science focused on cutaneous malignancies. It is not meant as a training program for graduate students, postdoctoral fellows, or clinical fellows in hematology-oncology, surgical oncology or dermatology. In collaboration with the Moffitt Lung SPORE, one CDP award per year may be co-supported by the Skin SPORE, promoting cross-SPORE fertilization. Dr. James Mule will lead the CDP. He has extensive experience in mentoring, research and administration, including serving as a faculty mentor/preceptor on numerous K08, K12, K99/R00 and ACS Fellowship awards, as well as the PI of two T32 training grants. Applications will be reviewed by an Award Evaluation Committee chaired by Dr. Mule using a scientific standard similar to a NIH study section. Scores of 1 (exceptional) to 9 (poor) will be assigned for categories of Significance, Innovation, Scientific quality. Collaboration, and Potential for publication and external funding;with brief justifications and overall impression), using a review form that we had employed previously for use in the CMRC. Progress reports will be required from all funded CDP project applicants at the end of the first six months, and again at the end of the first year of funding. The progress reports will be reviewed by the Award Evaluation Committee consisting of the Moffitt Skin SPORE IAC (see above for a list of members) and ad hoc members. Published manuscripts, abstracts accepted and the potential for translational impact will constitute the most important criteria for renewal of funding for an additional year.

Public Health Relevance

The Pre-SPORE grant at Moffitt expanded by the resources of the CMRC has previously chosen five investigators whose current cutaneous malignancy-related peer reviewed funding totals $1.2 million. Three of those faculty members are now among the funded investigators with proposals submitted as full Projects or to the DRP of the Moffitt Skin SPORE, which speaks to the potential significance and translational impact of the current CDP.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA168536-02
Application #
8754430
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
2
Fiscal Year
2014
Total Cost
$56,654
Indirect Cost
$23,031
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Rebecca, Vito W; Wood, Elizabeth; Fedorenko, Inna V et al. (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 13:1844-54
Kim, Sungjune; Ramakrishnan, Rupal; Lavilla-Alonso, Sergio et al. (2014) Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 63:1009-21
Smyth, Tomoko; Paraiso, Kim H T; Hearn, Keisha et al. (2014) Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 13:2793-804
Haarberg, H Eirik; Smalley, Keiran S M (2014) Resistance to Raf inhibition in cancer. Drug Discov Today Technol 11:27-32
Rebecca, Vito W; Smalley, Keiran S M (2014) Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol 91:417-25
Johnson, Douglas B; Smalley, Keiran S M; Sosman, Jeffrey A (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20:4186-92
Rebecca, Vito W; Alicea, Gretchen M; Paraiso, Kim H T et al. (2014) Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 27:1154-8
Cheng, Fengdong; Lienlaf, Maritza; Perez-Villarroel, Patricio et al. (2014) Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44-53
Rebecca, Vito W; Massaro, Renato R; Fedorenko, Inna V et al. (2014) Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 27:465-78
Fedorenko, Inna V; Fang, Bin; Koomen, John M et al. (2014) Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res 24:448-53